<DOC>
	<DOCNO>NCT00538681</DOCNO>
	<brief_summary>This study intend patient advanced , amenable surgery , metastatic lung cancer receive prior chemotherapy . The study conduct 2 part : - Part 1 intend evaluate safety pemetrexed + cisplatin + enzastaurin combination chemotherapy - Part 2 whose main objective compare efficacy pemetrexed + cisplatin + enzastaurin versus pemetrexed + cisplatin + placebo . Patients include Part 2 Nonsquamous NSCLC .</brief_summary>
	<brief_title>Study Patients With Advanced , Not Amenable Surgery , Metastatic Lung Cancer Comparing Treatment With Pemetrexed + Cisplatin + Enzastaurin Versus Pemetrexed + Cisplatin + Placebo</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>diagnosis advance nonsmall cell lung cancer ( NSCLC ) amenable curative treatment . Patients enrol Part 2 study must state diagnosis NSCLC also nonsquamous histology . prior systemic therapy ( chemotherapy , etc . ) pleurodesis chemotherapy disease prior radiotherapy allow must complete least 2 week study enrollment patient must recover acute toxic effect good performance status patient must sign informed consent document patient myocardial infarction occur less 6 month inclusion , uncontrolled arrhythmia , symptomatic angina pectoris , cardiac failure control medication patient unable swallow tablet patient take certain medicine control seizure activity , call `` enzyme inducing antiepileptic drug '' able stop take medicine prior enrol study patient unable interrupt aspirin and/or antiinflammatory agent patient unwilling unable take vitamin supplementation ( folic acid vitamin B12 ) medication prevent side effect</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>